Global Neurological Diseases Treatment Market (2021 to 2029) – by Drug Type, Diseases Type and Geography – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Neurological Diseases Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029” report has been added to ResearchAndMarkets.com’s offering.

This report offers strategic insights into the overall neurological diseases treatment market along with the market size and estimates for the duration 2019 to 2029. The said research study cover in-depth analysis of neurological treatment market segments based on type of drugs, diseases and different geographies further segmented by countries.

For the purpose of this study, the global neurological diseases treatment market is segmented on the basis of drug type into anticholinergic, antiepileptic, antipsychotic, hypnotic & sedative, analgesics, antihypertensive, anticoagulants, and others. Market size estimates and forecast for these segments for the period 2019 to 2029 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2021 to 2029, considering 2020 as the base year.

For the purpose of this study, the global neurological diseases treatment market is segmented on the basis of diseases type into epilepsy, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, cerebrovascular disease, and others. Market size estimates and forecast for these segments for the period 2019 to 2029 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2021 to 2029, considering 2020 as the base year.

The geographical segmentation of neurological diseases market comprised regions such as North America, Europe, Asia-Pacific, Latin America & Middle East and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, Mexico, Saudi Arabia, South Africa, and other countries. Market size and forecast for these segments during 2019 to 2029 and their CAGRs for the period 2021 to 2029 are provided in this report.

Companies Profiled

• Novartis AG
• GlaxoSmithKline plc
• Merck & Co.
• Bayer AG
• AstraZeneca plc
• Boehringer Ingelheim GmbH
• Teva Pharmaceutical Industries Ltd.
• F. Hoffmann-La Roche Ltd.
• Neurelis, Inc.
• SK Life Science
• GW Research Ltd.
• Zogenix, Inc.
• Eisai Co., Ltd.
• AZTherapies, Inc.
• Biogen, Inc.
• Intra-Cellular Therapies, Inc.
• Avid Radiopharmaceuticals
• Avanir Pharmaceuticals
• Janssen Research & Development, LLC
• Sunovion Pharmaceuticals, Inc.
• AbbVie, Inc.
• NeuroDerm Ltd.
• MedDay Pharmaceuticals SA

Key Topics Covered:

Chapter 1. Preface

Chapter 2. Executive Summary

2.1. Global Neurological Diseases Treatment Market Portraiture

2.2. Global Neurological Diseases Treatment Market, By Drug Type, 2020 (US$ Mn)

2.3. Global Neurological Diseases Treatment Market, By Diseases Type, 2020 (US$ Mn)

2.4. Global Neurological Diseases Treatment Market, by Geography, 2020 Vs 2029 (Value %)

Chapter 3. Neurological Diseases Treatment Market: Market Dynamics and Future Outlook

3.1. Market Overview

3.2. Neurological Diseases: Epidemiology

3.3. Neurological Diseases Treatment: Future Trends

3.4. Drivers

3.5. Challenges

3.6. Opportunities

3.7. Attractive Investment Proposition, by Geography, 2020

3.8. Major Agreements, Partnerships and Collaborations

3.9. Competitive Landscape

3.9.1. Competitive Landscape, by Key Players, 2020

Chapter 4. Global Neurological Diseases Treatment Market, by Drug Type, 2019 – 2029 (US$ Mn)

4.1. Overview

4.1.1. Attractive Investment Proposition: Global Neurological Diseases Treatment Market, by Drug Type

4.2. Anticholinergic

4.3. Antiepileptic

4.4. Antipsychotic

4.5. Hypnotic & Sedative

4.6. Analgesics

4.7. Antihypertensive

4.8. Anticoagulants

4.9. Others

Chapter 5. Global Neurological Diseases Treatment Market: Pipeline Analysis

5.1. Overview

5.2. Phase III (Market estimations by 2025)

5.3. Phase II (Qualitative Information)

5.4. Phase I (Qualitative Information)

5.5. Preclinical Studies (Quantitative Information)

Chapter 6. Global Neurological Diseases Treatment Market, by Disease, 2019 – 2029 (US$ Mn)

6.1. Overview

6.2. Epilepsy

6.3. Alzheimer’s disease

6.4. Parkinson’s disease

6.5. Multiple Sclerosis

6.6. Cerebrovascular disease

6.7. Others

Chapter 7. Global Neurological Diseases Treatment Market, by Geography, 2019 – 2029 (US$ Mn)

7.1. Overview

7.2. North America Neurological Diseases Treatment Market Analysis, 2019 – 2029

7.3. Europe Neurological Diseases Treatment Market Analysis, 2019 – 2029

7.4. Asia Pacific Neurological Diseases Treatment Market Analysis, 2019 – 2029

7.5. Latin America Neurological Diseases Treatment Market Analysis, 2019 – 2029

7.6. Middle East & Africa (MEA) Neurological Diseases Treatment Market Analysis, 2019 – 2029

Chapter 8. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/c70vet

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900